[18F]SITATE生长抑素受体PET示踪剂的组织离体验证

Nils F. Trautwein, Sven Mattern, Martina Hinterleitner, Gerald Reischl, Ralf Schirrmacher, Volker Steger, Silvio Nadalin, Konstantin Nikolaou, Johannes Schwenck, Stephan Singer, Christian la Fougère
{"title":"[18F]SITATE生长抑素受体PET示踪剂的组织离体验证","authors":"Nils F. Trautwein, Sven Mattern, Martina Hinterleitner, Gerald Reischl, Ralf Schirrmacher, Volker Steger, Silvio Nadalin, Konstantin Nikolaou, Johannes Schwenck, Stephan Singer, Christian la Fougère","doi":"10.2967/jnumed.125.269619","DOIUrl":null,"url":null,"abstract":"<p>Radiolabeled somatostatin analogs (SSAs), such as [<sup>68</sup>Ga]Ga-DOTA SSAs, have transformed imaging and therapeutic strategies. However, their use is constrained by the high cost of generators and their short half-life. In contrast, [<sup>18</sup>F]SITATE presents a promising alternative, offering the advantage of a longer half-life than <sup>68</sup>Ga, along with the cost-effectiveness of cyclotron-based production. This study evaluated the first histologic ex vivo validation of [<sup>18</sup>F]SITATE. <strong>Methods:</strong> This study retrospectively included 47 patients (57% male; mean age, 66.9 ± 14.9 y) with histologically confirmed well-differentiated neuroendocrine neoplasms who underwent [<sup>18</sup>F]SITATE PET followed by surgery within 4 mo. Lesion uptake was quantified using SUV<sub>mean</sub>, SUV<sub>peak</sub>, SUV<sub>max</sub>, and tumor-to-liver ratio (TLR). Histologic somatostatin receptor (SSTR) type 2 expression was determined using histological scores (H-scores), with thresholds defining SSTR scores 1–3. The accuracy of PET imaging for preoperative metastatic detection was evaluated against surgical histology. <strong>Results:</strong> PET imaging demonstrated a significant correlation between [<sup>18</sup>F]SITATE uptake (SUV<sub>mean</sub> and TLR) and SSTR type 2 H-scores (<em>r</em> = 0.618 and 0.622, respectively; <em>P</em> &lt; 0.0001). SSTR score 3 correlated with increased SUV<sub>mean</sub> and TLR (<em>P</em> &lt; 0.0001). Among 35 patients with primary resection and lymphadenectomy, PET achieved a sensitivity of 73.9% and specificity of 100%. <strong>Conclusion:</strong> [<sup>18</sup>F]SITATE PET imaging strongly correlates with histologic SSTR expression, demonstrating utility in staging and guiding therapeutic decisions in neuroendocrine neoplasms. This <sup>18</sup>F-labeled tracer shows specificity comparable to historical [<sup>68</sup>Ga]Ga-DOTA SSA data, whereas an increase in sensitivity for the detection of locoregional metastases appears possible. Further head-to-head comparisons of [<sup>18</sup>F]SITATE with traditional [<sup>68</sup>Ga]Ga-DOTA SSA and histologic validation are warranted to optimize its diagnostic accuracy and clinical impact.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Histologic Ex Vivo Validation of the [18F]SITATE Somatostatin Receptor PET Tracer\",\"authors\":\"Nils F. Trautwein, Sven Mattern, Martina Hinterleitner, Gerald Reischl, Ralf Schirrmacher, Volker Steger, Silvio Nadalin, Konstantin Nikolaou, Johannes Schwenck, Stephan Singer, Christian la Fougère\",\"doi\":\"10.2967/jnumed.125.269619\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Radiolabeled somatostatin analogs (SSAs), such as [<sup>68</sup>Ga]Ga-DOTA SSAs, have transformed imaging and therapeutic strategies. However, their use is constrained by the high cost of generators and their short half-life. In contrast, [<sup>18</sup>F]SITATE presents a promising alternative, offering the advantage of a longer half-life than <sup>68</sup>Ga, along with the cost-effectiveness of cyclotron-based production. This study evaluated the first histologic ex vivo validation of [<sup>18</sup>F]SITATE. <strong>Methods:</strong> This study retrospectively included 47 patients (57% male; mean age, 66.9 ± 14.9 y) with histologically confirmed well-differentiated neuroendocrine neoplasms who underwent [<sup>18</sup>F]SITATE PET followed by surgery within 4 mo. Lesion uptake was quantified using SUV<sub>mean</sub>, SUV<sub>peak</sub>, SUV<sub>max</sub>, and tumor-to-liver ratio (TLR). Histologic somatostatin receptor (SSTR) type 2 expression was determined using histological scores (H-scores), with thresholds defining SSTR scores 1–3. The accuracy of PET imaging for preoperative metastatic detection was evaluated against surgical histology. <strong>Results:</strong> PET imaging demonstrated a significant correlation between [<sup>18</sup>F]SITATE uptake (SUV<sub>mean</sub> and TLR) and SSTR type 2 H-scores (<em>r</em> = 0.618 and 0.622, respectively; <em>P</em> &lt; 0.0001). SSTR score 3 correlated with increased SUV<sub>mean</sub> and TLR (<em>P</em> &lt; 0.0001). Among 35 patients with primary resection and lymphadenectomy, PET achieved a sensitivity of 73.9% and specificity of 100%. <strong>Conclusion:</strong> [<sup>18</sup>F]SITATE PET imaging strongly correlates with histologic SSTR expression, demonstrating utility in staging and guiding therapeutic decisions in neuroendocrine neoplasms. This <sup>18</sup>F-labeled tracer shows specificity comparable to historical [<sup>68</sup>Ga]Ga-DOTA SSA data, whereas an increase in sensitivity for the detection of locoregional metastases appears possible. Further head-to-head comparisons of [<sup>18</sup>F]SITATE with traditional [<sup>68</sup>Ga]Ga-DOTA SSA and histologic validation are warranted to optimize its diagnostic accuracy and clinical impact.</p>\",\"PeriodicalId\":22820,\"journal\":{\"name\":\"The Journal of Nuclear Medicine\",\"volume\":\"35 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Nuclear Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2967/jnumed.125.269619\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.125.269619","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

放射标记的生长抑素类似物(SSAs),如[68Ga]Ga-DOTA SSAs,已经改变了成像和治疗策略。然而,它们的使用受到发电机成本高和半衰期短的限制。相比之下,[18F]SITATE提供了一个有希望的替代方案,具有比68Ga更长的半衰期的优势,以及基于回旋加速器的生产的成本效益。本研究评估了[18F]SITATE的首次离体组织学验证。方法:本研究回顾性纳入47例患者(男性57%;平均年龄(66.9±14.9岁),组织学证实为分化良好的神经内分泌肿瘤,在4个月内接受了[18F]SITATE PET,并进行了手术。病变摄取使用SUVmean、SUVpeak、SUVmax和肿瘤与肝比(TLR)进行量化。组织学生长抑素受体(SSTR) 2型表达采用组织学评分(h评分),阈值定义SSTR评分1-3。根据手术组织学评估PET成像术前转移检测的准确性。结果:PET显像显示[18F]SITATE摄取(SUVmean和TLR)与SSTR 2型h -评分有显著相关性(r分别为0.618和0.622;P & lt;0.0001)。SSTR评分3与SUVmean和TLR升高相关(P <;0.0001)。在35例原发性淋巴结切除术患者中,PET的敏感性为73.9%,特异性为100%。结论:[18F]SITATE PET成像与组织学上的SSTR表达密切相关,在神经内分泌肿瘤的分期和指导治疗决策中发挥了重要作用。这种18f标记的示踪剂显示出与历史[68Ga]Ga-DOTA SSA数据相当的特异性,而检测局部转移的敏感性可能会增加。需要进一步将[18F]SITATE与传统的[68Ga]Ga-DOTA SSA进行正面比较,并进行组织学验证,以优化其诊断准确性和临床效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Histologic Ex Vivo Validation of the [18F]SITATE Somatostatin Receptor PET Tracer

Radiolabeled somatostatin analogs (SSAs), such as [68Ga]Ga-DOTA SSAs, have transformed imaging and therapeutic strategies. However, their use is constrained by the high cost of generators and their short half-life. In contrast, [18F]SITATE presents a promising alternative, offering the advantage of a longer half-life than 68Ga, along with the cost-effectiveness of cyclotron-based production. This study evaluated the first histologic ex vivo validation of [18F]SITATE. Methods: This study retrospectively included 47 patients (57% male; mean age, 66.9 ± 14.9 y) with histologically confirmed well-differentiated neuroendocrine neoplasms who underwent [18F]SITATE PET followed by surgery within 4 mo. Lesion uptake was quantified using SUVmean, SUVpeak, SUVmax, and tumor-to-liver ratio (TLR). Histologic somatostatin receptor (SSTR) type 2 expression was determined using histological scores (H-scores), with thresholds defining SSTR scores 1–3. The accuracy of PET imaging for preoperative metastatic detection was evaluated against surgical histology. Results: PET imaging demonstrated a significant correlation between [18F]SITATE uptake (SUVmean and TLR) and SSTR type 2 H-scores (r = 0.618 and 0.622, respectively; P < 0.0001). SSTR score 3 correlated with increased SUVmean and TLR (P < 0.0001). Among 35 patients with primary resection and lymphadenectomy, PET achieved a sensitivity of 73.9% and specificity of 100%. Conclusion: [18F]SITATE PET imaging strongly correlates with histologic SSTR expression, demonstrating utility in staging and guiding therapeutic decisions in neuroendocrine neoplasms. This 18F-labeled tracer shows specificity comparable to historical [68Ga]Ga-DOTA SSA data, whereas an increase in sensitivity for the detection of locoregional metastases appears possible. Further head-to-head comparisons of [18F]SITATE with traditional [68Ga]Ga-DOTA SSA and histologic validation are warranted to optimize its diagnostic accuracy and clinical impact.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信